High Rates of Discontinuation of D2 Receptor Antagonists as First-Line Treatment of Tourette Syndrome in Children: A Retrospective Database Analysis (P11-6.001)
To assess discontinuation rates of D2 receptor antagonists (D2RAs) for the treatment of Tourette syndrome (TS) in a real-world setting.
Authors
- Cecilia Pettersson (ORCID: https://orcid.org/0000-0002-7777-2805)
- George B. Karkanias (ORCID: https://orcid.org/0009-0006-3510-5816)
- David A. Isaacs (ORCID: https://orcid.org/0000-0002-9860-1052)
- Jason Swindle (ORCID: https://orcid.org/0000-0003-2467-1610)
- Timothy Cunniff
- Kinga K. Tomczak (ORCID: https://orcid.org/0000-0001-7839-4116)
- Faizan Mazhar (ORCID: https://orcid.org/0000-0002-2818-1179)
- Stephen P. Wanaski
- Sarah Atkinson (ORCID: https://orcid.org/0000-0001-6971-7112)
- Firas Dabbous (ORCID: https://orcid.org/0000-0003-3713-3045)
- Frederick E. Munschauer
Institutions
- Ithaka Harbors (US)
- Boston Children's Hospital (US)
- Paragon Genomics (United States) (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210413
- Primary Topic
- Obsessive-Compulsive Spectrum Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00